HIV Prevention

The FDA expands dolutegravir treatment to newborns from birth to 4 weeks who weigh at least 2 kg.

No HIV acquisitions occurred among 315 cisgender and transgender women receiving long-acting cabotegravir PrEP in the real-world US OPERA Cohort, despite mostly short injection delays.

A randomized trial evaluated whether the 4CMenB vaccine prevents gonorrhea among adults at high risk for infection.

A US prescription claims study evaluated uptake and 2-year persistence among users of long-acting injectable cabotegravir for HIV PrEP.

Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...

In a phase 3b trial, monthly dapivirine ring and daily oral PrEP were assessed for safety, adherence, and acceptability in pregnancy.

A type III hybrid effectiveness–implementation trial compared community-based organization versus direct-to-consumer delivery of the Keep It Up! digital HIV prevention intervention for young men who have...

A large US cohort study evaluated the scale, patient characteristics, and retention outcomes of telemedicine-delivered HIV preexposure prophylaxis (PrEP), offering clinicians new data on how telePrEP is...

Start fast, suppress durably, and think beyond the viral load: this primary care–focused guide covers diagnosis, same-day antiretroviral therapy, monitoring, opportunistic infection prevention, vaccines,...

A pilot randomized trial found that offering immediate pre-exposure prophylaxis (PrEP) initiation with a 28-day starter pack in the emergency department did not improve PrEP use or retention compared with...